巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Bright Minds Biosciences

    DRUG
    0.950
    0.060
    5.94%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Bright Minds Biosciences - 延遲價格・最後更新於 10/08 9:30
    最高位
    0.963
    最低位
    0.950
    開市價
    --
    前收市價
    1.010
    成交量(千)
    0.89
    成交額(百萬)
    0.01
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    11.28
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    8.950 - 0.750
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Bright Minds Biosciences
    證券代碼
    DRUG.US
    所屬板塊
    Biotechnology
    公司業務
    Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
    發行量
    11846861
    公司總部
    19 Vestry Street
    公司網址
    https://www.brightmindsbio.com
    公司電話
    +1 647 865-8622
    暫無內容

    關於

    Bright Minds Biosciences(DRUG.US)所屬的行業板塊為Biotechnology。
    Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
    詳細公司背景可參考: https://www.brightmindsbio.com